



LIVE HEALTHIER, NATURALLY.

**ISODIOL INTERNATIONAL INC. PROVIDES UPDATE TO DELAY
IN FILING ANNUAL AND INTERIM FINANCIALS**

August 31, 2020 – Vancouver, BC – [Isodiol International Inc.](#) (CSE: [ISOL](#)) (OTCQB: [ISOLF](#)) (FSE: [LB6B.F](#)) (the “Company” or “Isodiol”) announces that, further to its news release of July 30, 2020, the Company wishes to provide an update with respect to the delay in the filing of its (i) audited annual financial statements for the year end March 31, 2020, related management discussion and analysis (“MD&A”), and annual certifications (together, the “**Annual Financial Statements**”); and (ii) interim financial statements for the three months ended June 30, 2020, related MD&A, and interim certifications (together, the “**Interim Financial Statements**”).

In connection with the late filing of the Annual Financial Statements and Interim Financial Statements, the Company is relying on the blanket relief provided by the Canadian Securities Administrators (the “CSA”). On May 20, 2020, the CSA issued a notice stating that securities regulators will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made between June 2, 2020 and August 31, 2020, as a result of the COVID-19 pandemic. As such, the Company is relying on such relief offered by British Columbia Securities Commission Instrument 51-517 (“**BCI 51-517**”).

As required by BCSC Instrument 51-517, and similar orders in the Company’s other reporting jurisdictions, the Company advises that until the Company has filed and announced the Annual Financial Statements and Interim Financial Statements, all management and other insiders are subject to the Company’s share trading and black-out policy that reflects the principals in section 9 of National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. In addition, the Company confirms that since its news release of July 30, 2020, there have been no material business developments in the Company other than those disclosed through subsequent news release(s).

The Company continues to work diligently with its auditor in order to file the Annual Financial Statements and Interim Financial Statements by the prescribed extended deadlines of September 14, 2020, and October 15, 2020, respectively.

Sincerely,

Andrew S. Alvis
President and Director,
Isodiol International, Inc.

Marcos Agramont
CEO and Director
Isodiol International, Inc.

Follow our Corporate updates on Facebook at <https://www.facebook.com/isodiol/>

on **Twitter** [@Isodiolintlinc](#) and on **Instagram** [@isodiol](#)

ISODIOL®

LIVE HEALTHIER, NATURALLY.

About Isodiol International Inc.

[Isodiol International Inc.](#) is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

ON BEHALF OF THE BOARD

ANDREW S. ALVIS

PRESIDENT & DIRECTOR

INVESTOR RELATIONS:

ir@isodiol.com

604-409-4409

MEDIA CONTACT:

media@isodiol.com

Forward-Looking Information: *This news release may contain certain forward-looking information and statements. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.*

The CSE has not reviewed, approved or disapproved the content of this news release.